AEON Biopharma Posts Q3 Gains with Strong ABP-450 Biosimilarity Data
IRVINE, CA — November 14, 2025 — AEON Biopharma announced its third-quarter 2025 financial results, highlighting strong operational progress,...
Alzheimer’s Disease artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Eli Lilly FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
IRVINE, CA — November 14, 2025 — AEON Biopharma announced its third-quarter 2025 financial results, highlighting strong operational progress,...
BRISBANE, CA – November 13, 2025 — Gate Bioscience announced the closing of an oversubscribed $65 million Series B...
